Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial)
S. Ramakrishnan (Oxford, United Kingdom), H. Jeffers (Oxford, United Kingdom), B. Langford-Wiley (Oxford, United Kingdom), J. Davies (Oxford, United Kingdom), M. Mahdi (Oxford, United Kingdom), C. A'Court (Carterton, United Kingdom), I. Binnian (Eyensham, United Kingdom), S. Bright (Witney, United Kingdom), S. Cartwright (Faringdon, United Kingdom), R. Fox (Bicester, United Kingdom), R. Russell (Oxford, United Kingdom), M. Bafadhel (London, United Kingdom)
Source: International Congress 2022 – ALERT 1: COPD and hospital management
Session: ALERT 1: COPD and hospital management
Session type: Clinical trials session
Number: 711
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Ramakrishnan (Oxford, United Kingdom), H. Jeffers (Oxford, United Kingdom), B. Langford-Wiley (Oxford, United Kingdom), J. Davies (Oxford, United Kingdom), M. Mahdi (Oxford, United Kingdom), C. A'Court (Carterton, United Kingdom), I. Binnian (Eyensham, United Kingdom), S. Bright (Witney, United Kingdom), S. Cartwright (Faringdon, United Kingdom), R. Fox (Bicester, United Kingdom), R. Russell (Oxford, United Kingdom), M. Bafadhel (London, United Kingdom). Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial). 711
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|